Explore Supplements Subscribe
The VerdictHIGH CONVICTIONVerdict Score 90

Lowering LDL works. Raising HDL doesn't.

At your next blood draw, ask for ApoB and a 10-year ASCVD risk calculation alongside the standard lipid panel. That gives you the picture LDL-C alone can't show.

  1. The most surprising finding: extreme-high HDL-C (above 80–90 mg/dL) is associated with 15% higher all-cause mortality, not lower. The U-shape kills the simple "more is better" story.
  2. What most people get wrong: most "statin intolerance" is nocebo. Open-label muscle pain rates run 5–20× the rates seen in blinded trials, and the StatinWISE rechallenge program shows 70–90% of intolerance disappears under blinding.
  3. What to actually do about it: get a lipid panel + ApoB by 40 (men) or 45 (women), translate the result into a 10-year ASCVD risk number, and decide based on absolute benefit, not a single LDL value.

Think of LDL particles as delivery trucks dropping cholesterol off in your artery walls. The more trucks circling, the more they get stuck and trigger plaque. The genetics confirm this — three different drugs that lower LDL through three different mechanisms produce the exact same drop in heart attacks per unit of LDL lowered. HDL was supposed to be the cleanup crew, but every drug that raised HDL without lowering LDL failed to cut events. The cargo number was never the real lever.

SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.

Cholesterol — LDL, HDL, and the Statin Controversy

Lowering LDL works. Raising HDL doesn't. The "good cholesterol" framing is a marketing decision, not a scientific one.

Partially Correct High Conviction Truth Engine 2026-04-30

At your next blood draw, ask for ApoB and a 10-year ASCVD risk number alongside the standard lipid panel.

Standard panels show cholesterol cargo. ApoB shows particle count. In high-triglyceride states, those numbers diverge — and particle count is what drives heart disease.

Takes one phone call. No equipment needed.

The Verdict

Lowering LDL works. Raising HDL doesn't. The rest is shared decision-making, not controversy.

Think of LDL particles as delivery trucks dropping cholesterol off in your artery walls. The more trucks circling, the more get stuck and seed plaque. The genetics confirm this — three different drugs that lower LDL through three different mechanisms produce the same drop in heart attacks per unit of LDL lowered. HDL was supposed to be the cleanup crew, but every drug that raised HDL without lowering LDL failed to cut events. The cargo number was never the real lever.

  1. The most surprising finding: extreme-high HDL-C (above 80–90 mg/dL) is associated with 15% higher all-cause mortality, not lower. The "more is better" story dies at the high end.
  2. What most people get wrong: most "statin intolerance" is nocebo. Open-label muscle pain rates run 5–20× the rates seen in blinded trials, and the StatinWISE rechallenge program shows 70–90% of intolerance disappears under blinding.
  3. What to actually do about it: get a lipid panel + ApoB by 40 (men) or 45 (women), translate the result into a 10-year ASCVD risk number, and decide based on absolute benefit, not a single LDL value.

Want the full evidence? Keep scrolling

The Practical Takeaway

Practical lipid panel and risk-stratified decision-making

Conviction

High

The headline claims (LDL causality, ApoB superiority in high-TG, statin population safety, HDL target failure) are anchored by Mendelian randomization, IPD meta-analyses across n>170,000, and convergent failures of every HDL-raising program. Multiple independent lines of evidence point the same way.

Per-claim breakdown:

  • LDL-C is causally upstream of ASCVD; lowering it reduces events near-linearly. HIGH
    What would change my mind
    A pre-registered Mendelian randomization study restricted to a high-saturated-fat / low-carbohydrate dietary background showing a weaker LDL-C → ASCVD slope than population MR would soften the universality claim. None has been done.
  • ApoB / non-HDL-C outperform LDL-C in high-TG / T2D / metabolic-syndrome populations. HIGH
  • Statins are safe at population scale; myalgia is mostly nocebo; T2D risk is real but small. HIGH
    What would change my mind
    A large blinded N-of-1 program (n>1,000) showing real (not nocebo) myalgia rates above 5% would shift the "mostly nocebo" framing. StatinWISE put the ceiling near 10–30% real, 70–90% nocebo; bigger trials with the same design are unlikely to flip the direction.
  • HDL-C concentration is not a viable treatment target. HIGH
  • Combination low/moderate statin + ezetimibe ± bempedoic acid matches high-intensity statin monotherapy on outcomes. MODERATE
  • LMHR keto phenotype escapes the LDL-causality rule. LOW
    What would change my mind
    A 5-year, ≥5,000-person blinded RCT in lean-mass-hyper-responders (LDL-C ≥190 on keto, ApoB ≥130, no other risk factors) randomized to statin + ezetimibe vs placebo with a MACE primary endpoint, showing no event difference, would upgrade LMHR from LOW to MODERATE.

Go Deeper

Want evidence-scored answers to health questions like this — without the podcast hype? Join The Verdict for free weekly reviews.

Subscribe — Free

Sources

  1. Baigent C et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. CTTC IPD meta-analysis.
  2. Cholesterol Treatment Trialists' Collaboration (2012). The effects of lowering LDL cholesterol with statin therapy on cause-specific mortality and major vascular events. Lancet 380:581–590.
  3. Ference BA et al. (2017). Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med 376:1721–1730. Mendelian randomization across three LDL-lowering pathways.
  4. Lee SH et al. (2025). Alternative LDL-C lowering strategies vs high-intensity statins in ASCVD: an individual-patient-data meta-analysis. JAMA Cardiol.
  5. Schandelmaier S et al. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. PMID 28616955. n=39,195 — null on mortality / MI / stroke.
  6. Athyros VG et al. (2004). Relationship between LDL-C and non-HDL-C levels and clinical outcome in GREACE. Curr Med Res Opin. PMID 15383187.
  7. Charlton-Menys V et al. (2009). Apolipoproteins, cardiovascular risk and statin response in T2D (CARDS). Diabetologia. PMID 18972097.
  8. Herrett E et al. (2021). StatinWISE: Statin Web-based Investigation of Side Effects. BMJ. N-of-1 myalgia rechallenge program.
  9. Norwitz NG, Soto-Mota A et al. (2024). Lean Mass Hyper-Responder phenotype on ketogenic diet — prospective coronary artery calcium progression cohort.
  10. Yang HS et al. (2023). Extremely high HDL-C and all-cause / cardiovascular / stroke mortality: a cohort meta-analysis.

Verdict Score

How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.

90 Strong evidence
80–100Strong evidence ◀
60–79Mixed but supportive
40–59Uncertain
0–39Weak support

Get weekly verdicts — no fluff, just evidence

Conviction-scored health research in your inbox. What works, what doesn't, and what the studies actually measured.

Subscribe free

Related free research

Performance
Body Recomposition — Who Can Actually Do It?
 Performance
Muscle Confusion vs Progressive Overload — The Verdict
 Performance
Travel and Fitness — Maintaining Progress

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts